Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone765-463-7175
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$70,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Endocyte (NASDAQ:ECYT) Frequently Asked Questions
What is Endocyte's stock symbol?
Endocyte trades on the NASDAQ under the ticker symbol "ECYT."
How were Endocyte's earnings last quarter?
Endocyte, Inc. (NASDAQ:ECYT) posted its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.01. The biopharmaceutical company had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative return on equity of 21.19% and a negative net margin of 32,296.09%. View Endocyte's Earnings History.
What price target have analysts set for ECYT?
4 equities research analysts have issued twelve-month price targets for Endocyte's shares. Their forecasts range from $21.00 to $21.00. On average, they anticipate Endocyte's stock price to reach $21.00 in the next year. View Analyst Price Targets for Endocyte.
What is the consensus analysts' recommendation for Endocyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endocyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Endocyte.
Has Endocyte been receiving favorable news coverage?
Press coverage about ECYT stock has trended somewhat positive on Friday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endocyte earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near term.
Who are some of Endocyte's key competitors?
Some companies that are related to Endocyte include Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Marina Biotech (MRNA), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), Array Biopharma (ARRY), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Endocyte own?
Who are Endocyte's key executives?
Endocyte's management team includes the folowing people:
- Mr. Michael A. Sherman, CEO, Pres & Director (Age 52)
- Mr. Michael T. Andriole, Chief Financial Officer (Age 45)
- Dr. Alison A. Armour, Chief Medical Officer (Age 54)
- Dr. Christopher P. Leamon, VP of R&D (Age 52)
- Dr. Philip S. Low, Co-Founder, Chief Science Officer & Director (Age 70)
Who are Endocyte's major shareholders?
Endocyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Opera Trading Capital (0.07%). Company insiders that own Endocyte stock include Alison A Armour, Beth Taylor, Christopher P Leamon, Katherine Parker, Michael A Sherman, Michael T Andriole and Philip S Low. View Institutional Ownership Trends for Endocyte.
Which institutional investors are buying Endocyte stock?
How do I buy shares of Endocyte?
Shares of ECYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Endocyte?
Endocyte has a market capitalization of $0.00 and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.
What is Endocyte's official website?
How can I contact Endocyte?
Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The biopharmaceutical company can be reached via phone at 765-463-7175.
MarketBeat Community Rating for Endocyte (NASDAQ ECYT)
MarketBeat's community ratings are surveys of what our community members think about Endocyte and other stocks. Vote "Outperform" if you believe ECYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ECYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
